Abstract 196P
Background
Short course Brachytherapy in locally advanced cervical cancer; safety and response rateShort course Brachytherapy in locally advanced cervical cancer; safety and response rate Overall treatment time (OTT) is an important index for local control in locally advanced cervical cancer patients who recieve definitive chemoradiation (External Beam Radiation Therapy (EBRT) plus Brachytherapy (BT) plus concomittant chemotherapy). In this study, we examined the efficiency and safety of reducing OTT by reducing duration of the brachytherapy to one week in intervention arm versus three weeks in control arm.
Methods
The study was a non-randomized open-label phase II clinical trial, carried out on 49 cervical cancer patients (26 in intervention group and 23 in control) who received EBRT concomitant with Cisplatin and then brachytherapy in order to deliver 60 Gray equivalent total doses in 2-Gy fractions (EQD2) to Intermediate Risk-Clinical Tumor Volume (IR-CTV) and 85-90 Gy EQD2 to High Risk-Clinical Tumor Volume (HR-CTV). In the intervention group, all brachytherapy sessions were performed in 1 week, while for the control group, it was administrated in 3 consecutive weeks. The participants were followed (Minimum follow up time was 6 month and median follow up time was 10 month) to assess response and toxicity of the treatment.
Results
Overall, more than 95% of study participants had a complete response (according to 3 month post-treatment imaging and physical examination) and more than 4.0% reported partial response, and no treatment failure was observed. The complete response in intervention and control groups was 96.1% and 95.6%, respectively (P value > 0.05). There was no difference in treatment side effects between the two groups.
Conclusions
considering that short course brachytherapy was non inferior to conventional course from point of Response Rate and Side Effects during follow up time; so this strategy can be considered as an option for reducing the OTT which can at least cause decreasing the costs. Studies with larger sample size and phase 3 are recommended.
Clinical trial identification
IRCT20200617047815N1.
Editorial acknowledgement
Legal entity responsible for the study
Tehran University of Medical Sciences.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
214P - Versican G3 domain promotes myeloma cell proliferation, migration and invasion via activation of FAK/STAT3 signaling
Presenter: Nidhi Gupta
Session: Poster viewing 03
215P - Prospective observational study to evaluate impact of metabolic tumor volume on baseline 18F FDG PET/CT and molecular markers on tumor response rate in patients with diffuse large B-cell lymphoma
Presenter: Ankur Mudgal
Session: Poster viewing 03
216P - Lenalidomide maintenance after whole brain radiotherapy in relapsed/refractory primary CNS lymphoma
Presenter: Bhausaheb Bagal
Session: Poster viewing 03
217P - Role of copper levels in patients with myelodysplastic syndromes
Presenter: Revanth Boddu
Session: Poster viewing 03
218P - Prognostic role of apoptotic index in acute lymphoblastic leukemia
Presenter: Ramya Ramesh
Session: Poster viewing 03
219TiP - Randomised controlled study to compare efficacy & safety of KRd versus VRd regimens in newly diagnosed multiple myeloma using weekly schedule of generic carfilzomib
Presenter: Jasmine Porwal
Session: Poster viewing 03
233P - Cancer awareness, tobacco use and cessation among Malayali tribes, Yelagiri Hills, Tamil Nadu, India: A 8-year follow up study
Presenter: Delfin Lovelina Francis
Session: Poster viewing 03
234P - Epithelial-mesenchymal transition and cancer stem cells: Missing link in oral squamous cell carcinoma
Presenter: Selvaraj Jayaraman
Session: Poster viewing 03
235P - Evaluation of a prognostic model for head and neck cutaneous squamous cell carcinoma using a cumulative number of risk factors
Presenter: Reiichi Doi
Session: Poster viewing 03
236P - Chrono-chemotherapy combined with radiotherapy for locally advanced nasopharyngeal carcinoma: A meta-analysis
Presenter: Jianquan Yang
Session: Poster viewing 03